# Constructive Bio

> Constructive Bio enables the design and manufacture of proteins with non\-canonical amino acids — new medicines and materials at scale\.

Generated by Yoast SEO v28.0, this is an llms.txt file, meant for consumption by LLMs.

## Pages
- [About](https://constructive.bio/about/): Constructive Bio is a biotechnology company that expanded the genetic code to manufacture ncAA proteins and peptides beyond natural chemistry\.
- [Contact](https://constructive.bio/contact/)
- [Design](https://constructive.bio/design/): Constructive Bio enables new chemistry with non\-canonical amino acid design that natural biology could never reach\.
- [Make](https://constructive.bio/make/): BioForge is our non\-canonical amino acid manufacturing platform — we make peptides and proteins with novel chemistry at industry scale\.
- [Cure](https://constructive.bio/cure/): Our platform enables ncAA therapeutics: site\-specific ADCs, engineered cytokines, covalent biologics, and oral peptides\.
- [Insights](https://constructive.bio/insights/): Press releases, publications, and white papers from Constructive Bio on non\-canonical amino acid design and manufacturing\.
- [Partnering](https://constructive.bio/partnering/)
- [Non\-canonical Amino Acids](https://constructive.bio/ncaa/)

## Awards
- [Constructive Bio shortlisted for One Nucleus Awards 2026: best use of emerging technology](https://constructive.bio/award/constructive-bio-shortlisted-for-one-nucleus-awards-2026-best-use-of-emerging-technology/)

## ncAAs
- [Enhanced catalytic activity](https://constructive.bio/ncaa/enhanced-catalytic-activity/)
- [Architecture](https://constructive.bio/ncaa/peptide-architecture/)
- [Enhanced ADC linkers](https://constructive.bio/ncaa/enhanced-adc-linkers/)
- [Catalysis](https://constructive.bio/ncaa/catalysis/)
- [Stability, binding](https://constructive.bio/ncaa/stability-binding/)

## News
- [Constructive Bio appoints biopharma leader Jim Weissman to its Board of Directors](https://constructive.bio/news/constructive-bio-appoints-biopharma-leader-jim-weissman-to-its-board-of-directors/): Constructive Bio, a leading synthetic biology company, today announces the appointment of Jim Weissman to its Board of Directors\.
- [Constructive Bio shortlisted for One Nucleus Awards 2026: best use of emerging technology](https://constructive.bio/news/constructive-bio-one-nucleus-awards-2026-best-emerging-technology-shortlist/): Constructive Bio has been shortlisted for the One Nucleus Awards 2026 in the best use of emerging technology category for its whole\-genome synthesis and engineered translation platform\.
- [The Observer Features Constructive Bio's Sustainable Fermentation Alternative to Peptide Manufacturing Waste](https://constructive.bio/news/observer-constructive-bio-sustainable-fermentation-peptide-manufacturing-waste/): The Observer featured Constructive Bio in coverage of environmental challenges in peptide drug manufacturing, highlighting the company's fermentation\-based approach as a sustainable alternative to chemical synthesis\.
- [Constructive Bio Raises $58M Series A to Scale Fermentation\-Based Peptide Manufacturing with Non\-Canonical Amino Acids](https://constructive.bio/news/constructive-bio-58m-series-a-fermentation-peptide-manufacturing-ncaa/): Constructive Bio secured $58 million in Series A financing, bringing total funding to $75 million, to scale its BioForge fermentation platform for manufacturing peptide therapeutics with non\-canonical amino acids \(ncAAs\)\.
- [Constructive Bio Licences tRNA Display Technology for Incorporating Non\-Canonical Amino Acids into Peptides and Proteins](https://constructive.bio/news/constructive-bio-trna-display-licence-ncaa-peptides-proteins/): Constructive Bio has secured an exclusive licence for tRNA display technology, enabling directed integration of non\-canonical amino acids \(ncAAs\) and other new\-to\-nature building blocks into peptides and proteins\.

## Publications
- [Cell\-Based Synthesis of Non\-Natural Peptide and Depsipeptide Macrocycles Using Genetically Programmed ncAA Incorporation](https://constructive.bio/publication/macrocycles/): This is the most direct scientific proof\-of\-concept for Constructive Bio's commercial proposition\. It demonstrates that peptide macrocycles
- [Syn57: E\. coli Engineered with the Most Compressed Genetic Code Ever Created, Freeing Seven Codons for ncAA Incorporation](https://constructive.bio/publication/syn57/): Syn57 dramatically expands the 'codon space' available for non\-canonical amino acid incorporation, from three freed codons in Syn61 to seven in Syn57\. For peptide therapeutics, this means Constructive Bio's platform can now encode a much wider range of non\-natural chemistries into a single molecule, enabling peptide drugs with enhanced metabolic stability, novel mechanisms of action, and properties not achievable through traditional solid\-phase peptide synthesis \(SPPS\)\.
- [REXER and GENESIS: The Genome Writing Toolkit for Creating Custom Synthetic Genomes in E\. coli](https://constructive.bio/publication/rexer-and-genesis-the-genome-writing-toolkit-for-creating-custom-synthetic-genomes-in-e-coli/): REXER and GENESIS are the 'how' behind Constructive Bio's genome synthesis capability\. They enable the precise, large\-scale rewriting of bacterial genomes that produces the company's recoded production organisms\. Having a published, validated protocol in Nature Protocols demonstrates the robustness and reproducibility of the approach that underpins the BioForge platform\.
- [Systematic Synonymous Codon Compression Demonstrates Genome\-Scale Codon Removal Is Viable in E\. coli](https://constructive.bio/publication/synonymous-codon-compression/): This was the proof\-of\-principle that codon compression works at genome scale\. Before this paper, it was unclear whether removing synonymous codons across an entire genome was feasible\. The demonstration that E\. coli tolerates systematic codon removal opened the path to Syn61 and Syn57, and ultimately to Constructive Bio's commercial platform for manufacturing peptide therapeutics with expanded genetic codes\.
- [Phage Display with Multiple Non\-Canonical Amino Acids Enables ncAA\-Containing Peptide Library Screening for Drug Discovery](https://constructive.bio/publication/phage-display-multiple-ncaas/): Drug discovery requires screening large libraries to find peptide candidates\. This work enables those libraries to include non\-canonical amino acids from the outset, rather than adding them later through chemical modification\. Combined with the tRNA display technology that Constructive Bio has exclusively licenced, this creates an end\-to\-end discovery\-to\-manufacturing pipeline for ncAA\-containing peptide therapeutics\.

## Whitepapers
- [Non\-canonical amino acids and programmable biomolecules](https://constructive.bio/whitepaper/non-canonical-amino-acids-and-programmable-biomolecules/): Non\-canonical amino acids expand the building blocks of biology beyond nature’s standard set, enabling programmable peptides, proteins, macrocycles, and polymers with properties not found in nature\.
- [Genome synthesis: how to write a genome at scale](https://constructive.bio/whitepaper/genome-synthesis-how-to-write-a-genome-at-scale/): Genome synthesis is the ability to write DNA at the scale of entire chromosomes and genomes\. It is fundamentally different from gene editing, and it enables applications that editing cannot reach\.
- [Genetic code expansion: How recoded genomes unlock new biology](https://constructive.bio/whitepaper/genetic-code-expansion-how-recoded-genomes-unlock-new-biology/): Genetic code expansion uses whole\-genome recoding to free up codons and assign them to amino acids that biology has never used, opening new routes to drug discovery and sustainable manufacturing\.
- [24 recent non\-canonical amino acid breakthroughs](https://constructive.bio/whitepaper/24-recent-non-canonical-amino-acid-breakthroughs/): Non\-canonical amino acids expand the building blocks of biology beyond nature's standard set, enabling programmable peptides, proteins, macrocycles, and polymers with properties not found in nature\.

## Content Types
- [Publication](https://constructive.bio/custom-content-type/publication/)
- [Company](https://constructive.bio/custom-content-type/company/)
- [Award](https://constructive.bio/custom-content-type/award/)
- [News](https://constructive.bio/custom-content-type/news/)
- [Whitepaper](https://constructive.bio/custom-content-type/whitepaper/)

## News Tags
- [synthetic\-biology](https://constructive.bio/news-tag/synthetic-biology/)
- [biomanufacturing](https://constructive.bio/news-tag/biomanufacturing/)
- [platform](https://constructive.bio/news-tag/platform/)
- [ncaa](https://constructive.bio/news-tag/ncaa/)
- [team](https://constructive.bio/news-tag/team/)

## Whitepaper Tags
- [biomanufacturing](https://constructive.bio/whitepaper-tag/biomanufacturing/)
- [peptide\-therapeutics](https://constructive.bio/whitepaper-tag/peptide-therapeutics/)
- [ncaa](https://constructive.bio/whitepaper-tag/ncaa/)
- [genetic\-code\-expansion](https://constructive.bio/whitepaper-tag/genetic-code-expansion/)
- [fermentation](https://constructive.bio/whitepaper-tag/fermentation/)

## Optional
- [Sitemap index](https://constructive.bio/sitemap_index.xml)